These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22884950)

  • 1. Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.
    Thudium KE; Ghoshal S; Fetterly GJ; Haese JP; Karpf AR; Wetzler M
    Leuk Res; 2012 Nov; 36(11):1410-6. PubMed ID: 22884950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
    Link PA; Baer MR; James SR; Jones DA; Karpf AR
    Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
    Valdez BC; Li Y; Murray D; Champlin RE; Andersson BS
    Biochem Pharmacol; 2011 Jan; 81(2):222-32. PubMed ID: 20933509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
    Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
    Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
    Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
    Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ; Schneider P; Pieters R; Stam RW
    Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
    Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
    Månsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
    Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
    Song G; Valdez BC; Li Y; Dominguez JR; Corn P; Champlin RE; Andersson BS
    Leuk Lymphoma; 2014 Jul; 55(7):1625-34. PubMed ID: 24144307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of clofarabine in acute myeloid leukemia.
    Ghanem H; Kantarjian H; Ohanian M; Jabbour E
    Leuk Lymphoma; 2013 Apr; 54(4):688-98. PubMed ID: 22957815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofarabine: past, present, and future.
    Kantarjian HM; Jeha S; Gandhi V; Wess M; Faderl S
    Leuk Lymphoma; 2007 Oct; 48(10):1922-30. PubMed ID: 17852710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML.
    Rosen DB; Cordeiro JA; Cohen A; Lacayo N; Hogge D; Hawtin RE; Cesano A
    Leuk Res; 2012 Jul; 36(7):900-4. PubMed ID: 22521550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clofarabine: emerging role in leukemias.
    Sampat K; Kantarjian H; Borthakur G
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1559-64. PubMed ID: 19715446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
    Xie C; Edwards H; Lograsso SB; Buck SA; Matherly LH; Taub JW; Ge Y
    Pediatr Blood Cancer; 2012 Dec; 59(7):1245-51. PubMed ID: 22488775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
    Robak T; Szmigielska-Kapłon A; Pluta A; Grzybowska-Izydorczyk O; Wolska A; Czemerska M; Wierzbowska A
    Curr Med Chem; 2011; 18(5):638-66. PubMed ID: 21182488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical modulation of cytarabine triphosphate by clofarabine.
    Cooper T; Ayres M; Nowak B; Gandhi V
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):361-368. PubMed ID: 15723262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
    Lech-Maranda E; Korycka A; Robak T
    Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
    Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
    Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofarabine targets the large subunit (α) of human ribonucleotide reductase in live cells by assembly into persistent hexamers.
    Aye Y; Brignole EJ; Long MJ; Chittuluru J; Drennan CL; Asturias FJ; Stubbe J
    Chem Biol; 2012 Jul; 19(7):799-805. PubMed ID: 22840768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired S-phase arrest in acute myeloid leukemia cells with a FLT3 internal tandem duplication treated with clofarabine.
    Seedhouse C; Grundy M; Shang S; Ronan J; Pimblett H; Russell N; Pallis M
    Clin Cancer Res; 2009 Dec; 15(23):7291-8. PubMed ID: 19934300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.